CN113597313A - 用于治疗和预防微血栓形成的纤溶酶原 - Google Patents

用于治疗和预防微血栓形成的纤溶酶原 Download PDF

Info

Publication number
CN113597313A
CN113597313A CN202080021518.7A CN202080021518A CN113597313A CN 113597313 A CN113597313 A CN 113597313A CN 202080021518 A CN202080021518 A CN 202080021518A CN 113597313 A CN113597313 A CN 113597313A
Authority
CN
China
Prior art keywords
plasminogen
patient
plg
glu
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080021518.7A
Other languages
English (en)
Chinese (zh)
Inventor
S·T·基西希
R·威尔茨
H·R·格尔丁
M·马楚尔
H-J·安德斯
C·X·史
C·施梅芬尼
S·K·德瓦拉普
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Foresight Pharmaceutical Consulting Co
Original Assignee
Foresight Pharmaceutical Consulting Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Foresight Pharmaceutical Consulting Co filed Critical Foresight Pharmaceutical Consulting Co
Publication of CN113597313A publication Critical patent/CN113597313A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202080021518.7A 2019-01-24 2020-01-24 用于治疗和预防微血栓形成的纤溶酶原 Pending CN113597313A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19153572.3 2019-01-24
EP19153572 2019-01-24
PCT/EP2020/051733 WO2020152322A1 (en) 2019-01-24 2020-01-24 Plasminogen for treating and preventing microthrombosis

Publications (1)

Publication Number Publication Date
CN113597313A true CN113597313A (zh) 2021-11-02

Family

ID=65234430

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080021518.7A Pending CN113597313A (zh) 2019-01-24 2020-01-24 用于治疗和预防微血栓形成的纤溶酶原

Country Status (9)

Country Link
US (1) US20220072110A1 (https=)
EP (1) EP3914288A1 (https=)
JP (1) JP2022518496A (https=)
KR (1) KR20210119428A (https=)
CN (1) CN113597313A (https=)
AU (1) AU2020212404B2 (https=)
BR (1) BR112021014068A2 (https=)
CA (1) CA3127375A1 (https=)
WO (1) WO2020152322A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022258590A1 (en) 2021-06-08 2022-12-15 Previpharma Consulting Gmbh Process for isolating plasminogen from a blood plasma fraction
WO2025132796A1 (en) 2023-12-21 2025-06-26 Previpharma Consulting Gmbh Process for isolating glu-plasminogen from a solution

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108472342A (zh) * 2015-12-18 2018-08-31 泰伦基国际有限公司 一种用于预防或治疗急性及慢性血栓的方法
WO2018162754A1 (en) * 2017-03-09 2018-09-13 Previpharma Consulting Gmbh Preparing and use of glu-plasminogen from blood fractions
CN109069567A (zh) * 2015-12-18 2018-12-21 泰伦基国际有限公司 一种预防或治疗糖尿病性神经损伤及其相关病症的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2254316B1 (https=) * 1973-12-18 1977-04-22 Choay Sa
US5520912A (en) 1993-07-02 1996-05-28 Immuno Aktiengesellschaft Prevention and treatment of ischemic events and reperfusion injury resulting therefrom using lys-plasminogen
TWI801331B (zh) * 2015-11-03 2023-05-11 美商波麥堤克生物治療股份有限公司 纖維蛋白溶酶原缺乏症之纖維蛋白溶酶原替代療法
DK3391902T5 (da) * 2015-12-18 2024-09-23 Talengen Int Ltd Plasminogen til anvendelse i behandlingen af diabetisk angiokardiopati

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108472342A (zh) * 2015-12-18 2018-08-31 泰伦基国际有限公司 一种用于预防或治疗急性及慢性血栓的方法
CN109069567A (zh) * 2015-12-18 2018-12-21 泰伦基国际有限公司 一种预防或治疗糖尿病性神经损伤及其相关病症的方法
WO2018162754A1 (en) * 2017-03-09 2018-09-13 Previpharma Consulting Gmbh Preparing and use of glu-plasminogen from blood fractions

Also Published As

Publication number Publication date
AU2020212404B2 (en) 2025-11-27
WO2020152322A1 (en) 2020-07-30
KR20210119428A (ko) 2021-10-05
JP2022518496A (ja) 2022-03-15
EP3914288A1 (en) 2021-12-01
US20220072110A1 (en) 2022-03-10
AU2020212404A1 (en) 2021-08-26
BR112021014068A2 (pt) 2021-09-21
CA3127375A1 (en) 2020-07-30

Similar Documents

Publication Publication Date Title
Innerfield et al. Parenteral administration of trypsin: clinical effect in 538 patients
López-Beret et al. Low molecular weight heparin versus oral anticoagulants in the long-term treatment of deep venous thrombosis
McKenna Abnormal coagulation in the postoperative period contributing to excessive bleeding
Kwaan et al. Fibrinolytic activity in lesions of hereditary hemorrhagic telangiectasia
CN110612350A (zh) 源自血液的谷氨酸-纤溶酶原的制备和使用
US12590301B2 (en) Methods for safe and effective thrombolysis using sequential administration of tissue plasminogen activator and mutant pro-urokinase
CN113597313A (zh) 用于治疗和预防微血栓形成的纤溶酶原
Gelwix et al. Warfarin-induced skin necrosis
Pedersen et al. Plasminogen activator inhibitor type-1 determines plasmin formation in patients with ischaemic heart disease
LeVeen et al. Venous and arterial occlusive disease treated by enzymatic clot lysis
RU2813699C2 (ru) Плазминоген для лечения и профилактики микротромбоза
Novacek et al. Enhanced blood coagulation and enhanced fibrinolysis during hemodialysis with prostacyclin
Le Sache et al. Recombinant activated factor VII and prothrombin complex concentrates have different effects on bleeding and arterial thrombosis in the haemodiluted rabbit
Di Perri et al. Defibrotide therapy for thrombophlebitis–controlled clinical trial
Chesterman et al. Thrombolytic therapy with streptokinase
JP2012519674A (ja) フィブリノーゲンの新規な使用
Brown et al. Anticoagulation
Sharnoff Prevention of venous thrombosis and pulmonary embolism
Frade Hypercoagulable State in Trauma Patients
DK175116B1 (da) Vævsfaktorprotein-antagonist til farmaceutisk anvendelse, anvendelse af vævsfaktorprotein-antagonister til fremstilling af et lægemiddel til behandling af hyperkoagulativ blödningsforstyrrelse, og terapeutisk doseringsform
WO2021214320A1 (en) Plasminogen for use in treating and preventing lung dysfunction
Wilson Venous thromboembolism
Bick et al. Abstracts of Current Literature
HK1243666B (en) Methods and compositions for safe and effective thrombolysis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20211102